Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472368 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00472368 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT00472368, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This single center study will help determine the absorption, metabolism, and excretion of LBH589 and to assess the safety and efficacy of LBH589 in advanced cancer patients for whom no standard therapy exists.
Interventions
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00472368
The ClinicalTrials.gov registry entry for NCT00472368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589 is the first listed.
NCT00472368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00472368 about?
NCT00472368 is a clinical study titled "A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589". This single center study will help determine the absorption, metabolism, and excretion of LBH589 and to assess the safety and efficacy of LBH589 in advanced cancer patients for whom no standard therapy exists.
What is the current status of trial NCT00472368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2007-05.
What interventions are being tested in trial NCT00472368?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT00472368?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.